Skip to main content
Top
Published in: Journal of Translational Medicine 1/2009

Open Access 01-12-2009 | Commentary

Perfused human organs versus Mary Shelley's Frankenstein

Author: Lawrence Leung

Published in: Journal of Translational Medicine | Issue 1/2009

Login to get access

Abstract

Novel drugs have to go through mandatory pre-clinical testing before they can be approved for use in clinical trials. In essence, it is a form of bench-to-bedside (N2B) translational medicine, but the wastage rate of target candidates is immensely high. Effects seen in vitro often do not translate to in vivo human settings. The search is on for better models closer to human physiology to be used in pre-clinical drug screening. The Ex Vivo Metrics© system has been introduced where a human organ is harvested and revitalized in a controlled environment suitable for testing of both drug efficacy and potential toxicity. This commentary expresses the author's views regarding this technology of perfused human organs.
Literature
1.
go back to reference Pardridge WM: Translational science: what is it and why is it so important?. Drug Discov Today. 2003, 8 (18): 813-815. 10.1016/S1359-6446(03)02823-X.CrossRefPubMed Pardridge WM: Translational science: what is it and why is it so important?. Drug Discov Today. 2003, 8 (18): 813-815. 10.1016/S1359-6446(03)02823-X.CrossRefPubMed
2.
go back to reference Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U: Correction of X-linked Chronic Granulomatous Disease by Gene Therapy, Augmented by Insertional Activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006, 12 (4): 401-409. 10.1038/nm1393.CrossRefPubMed Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U: Correction of X-linked Chronic Granulomatous Disease by Gene Therapy, Augmented by Insertional Activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006, 12 (4): 401-409. 10.1038/nm1393.CrossRefPubMed
3.
go back to reference Palfi S: Towards gene therapy for Parkinson's disease. The Lancet Neurology. 2008, 7 (5): 375-376. 10.1016/S1474-4422(08)70066-8.CrossRefPubMed Palfi S: Towards gene therapy for Parkinson's disease. The Lancet Neurology. 2008, 7 (5): 375-376. 10.1016/S1474-4422(08)70066-8.CrossRefPubMed
4.
5.
go back to reference Davies H: Can Mary Shelley's Frankenstein be read as an early research ethics text?. Med Humanit. 2004, 30 (1): 32-35. 10.1136/jmh.2003.000153.CrossRefPubMed Davies H: Can Mary Shelley's Frankenstein be read as an early research ethics text?. Med Humanit. 2004, 30 (1): 32-35. 10.1136/jmh.2003.000153.CrossRefPubMed
Metadata
Title
Perfused human organs versus Mary Shelley's Frankenstein
Author
Lawrence Leung
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-7-9

Other articles of this Issue 1/2009

Journal of Translational Medicine 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine